Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base
Retrieved on:
星期一, 八月 30, 2021
CSE, Program, Research, Health, Lists of diseases, Public health, Safety, OTC, Solution, Rapids, Psilocybin, Suicide, Disorder, Esketamine, Software, American Journal, Ta' Braxia Cemetery, TRD, Forward-looking statement, Risk, Psychiatry, Disclosure, SEDAR, Nursing, CEO, Brain, Industry, The American Journal of Psychiatry, Completeness, Electroconvulsive therapy, IV, Person, Guideline, Randomized controlled trial, Removal of cannabis from Schedule I of the Controlled Substances Act, Depression, Controlled Drugs and Substances Act, Health Canada, Education, Mission statement, Company, Drug prohibition law, FWB, Science, CDSA, Physician, Psychotherapy, System, Marketing, Multimedia, News, Patient, Euro-Excellence Inc v Kraft Canada Inc, Medical device, Pharmaceutical industry, Risk management, Medicine, Audit
"In addition to our clinics, we are executing on our strategy to test out innovative formulations and delivery methods.
Key Points:
- "In addition to our clinics, we are executing on our strategy to test out innovative formulations and delivery methods.
- Increasing Patient Volume:Braxia Scientific, through its four multidisciplinary, community-based Canadian clinics, operating as Braxia Health, continued to see increased patient volume, exceeding its IV ketamine infusion targets every month since January 2021.
- The Company is confident that the study will demonstrate that the Company can effectively conduct a randomized controlled trial using psychedelic-assisted therapy.
- Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.